The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial

John E Lewis, Steven E. Atlas, Muhammad H. Abbas, Ammar Rasul, Ashar Farooqi, Laura A. Lantigua, Frederick Michaud, Sharon Goldberg, Lucas C. Lages, Oscar L. Higuera, Andrea Fiallo, Eduard Tiozzo, Judi Woolger, Stephanie Ciraula, Armando J Mendez, Allan E Rodriguez, Janet Konefal

Research output: Contribution to journalArticle

Abstract

The primary objective of the study was to evaluate the effects of a hydrolyzed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, hepatic, and renal function in HIV + individuals. A six-month randomized double-blind placebo-controlled trial was utilized to conduct the intervention. Forty-seven HIV + participants on stable antiretroviral therapy were enrolled and randomly assigned to one of the two study conditions (n = 22 RBAC and n = 25 placebo) and consumed 3 gram/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months follow-up for CD4+ and CD8+, liver enzymes, and kidney function. No side effects were reported, and liver and kidney markers nearly remained completely within normal limits. The percentage change in CD4+ was similar for the placebo (+2.2%) and RBAC (+3.1%) groups at 6 months follow-up. The percentage change in CD8+ count significantly decreased from baseline to 6 months in the RBAC group (−5.2%), whereas it increased in the placebo group (+57.8%; p = 0.04). The CD4+/CD8+ ratio improved clinically in the RBAC group from 0.95 (SD =0.62) at baseline to 1.07 (SD =0.11) at 6 months, whereas it declined in the placebo group from 0.96 (SD =0.80) at baseline to 0.72 (SD =0.59) at 6 months. Our results showed a statistically significant decrease in CD8+ count and a clinically significant increase in CD4+/CD8+ ratio for the RBAC group compared to the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.

Original languageEnglish (US)
JournalJournal of Dietary Supplements
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

arabinoxylan
liver function
rice bran
renal function
Dietary Supplements
placebos
Polysaccharides
dietary supplements
polysaccharides
Placebos
HIV
Kidney
Liver
CD4-CD8 Ratio
liver
Oryza
adverse effects
kidneys
therapeutics
Enzymes

Keywords

  • arabinoxylan
  • CD4-CD8 ratio
  • CD8
  • dietary supplements
  • HIV infections
  • immune system phenomena
  • polysaccharides

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics
  • Pharmacology (medical)

Cite this

The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial. / Lewis, John E; Atlas, Steven E.; Abbas, Muhammad H.; Rasul, Ammar; Farooqi, Ashar; Lantigua, Laura A.; Michaud, Frederick; Goldberg, Sharon; Lages, Lucas C.; Higuera, Oscar L.; Fiallo, Andrea; Tiozzo, Eduard; Woolger, Judi; Ciraula, Stephanie; Mendez, Armando J; Rodriguez, Allan E; Konefal, Janet.

In: Journal of Dietary Supplements, 01.01.2018.

Research output: Contribution to journalArticle

Lewis, JE, Atlas, SE, Abbas, MH, Rasul, A, Farooqi, A, Lantigua, LA, Michaud, F, Goldberg, S, Lages, LC, Higuera, OL, Fiallo, A, Tiozzo, E, Woolger, J, Ciraula, S, Mendez, AJ, Rodriguez, AE & Konefal, J 2018, 'The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial', Journal of Dietary Supplements. https://doi.org/10.1080/19390211.2018.1494661
Lewis, John E ; Atlas, Steven E. ; Abbas, Muhammad H. ; Rasul, Ammar ; Farooqi, Ashar ; Lantigua, Laura A. ; Michaud, Frederick ; Goldberg, Sharon ; Lages, Lucas C. ; Higuera, Oscar L. ; Fiallo, Andrea ; Tiozzo, Eduard ; Woolger, Judi ; Ciraula, Stephanie ; Mendez, Armando J ; Rodriguez, Allan E ; Konefal, Janet. / The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial. In: Journal of Dietary Supplements. 2018.
@article{cbb7980d63b544c4925620d28f5083c1,
title = "The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial",
abstract = "The primary objective of the study was to evaluate the effects of a hydrolyzed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, hepatic, and renal function in HIV + individuals. A six-month randomized double-blind placebo-controlled trial was utilized to conduct the intervention. Forty-seven HIV + participants on stable antiretroviral therapy were enrolled and randomly assigned to one of the two study conditions (n = 22 RBAC and n = 25 placebo) and consumed 3 gram/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months follow-up for CD4+ and CD8+, liver enzymes, and kidney function. No side effects were reported, and liver and kidney markers nearly remained completely within normal limits. The percentage change in CD4+ was similar for the placebo (+2.2{\%}) and RBAC (+3.1{\%}) groups at 6 months follow-up. The percentage change in CD8+ count significantly decreased from baseline to 6 months in the RBAC group (−5.2{\%}), whereas it increased in the placebo group (+57.8{\%}; p = 0.04). The CD4+/CD8+ ratio improved clinically in the RBAC group from 0.95 (SD =0.62) at baseline to 1.07 (SD =0.11) at 6 months, whereas it declined in the placebo group from 0.96 (SD =0.80) at baseline to 0.72 (SD =0.59) at 6 months. Our results showed a statistically significant decrease in CD8+ count and a clinically significant increase in CD4+/CD8+ ratio for the RBAC group compared to the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.",
keywords = "arabinoxylan, CD4-CD8 ratio, CD8, dietary supplements, HIV infections, immune system phenomena, polysaccharides",
author = "Lewis, {John E} and Atlas, {Steven E.} and Abbas, {Muhammad H.} and Ammar Rasul and Ashar Farooqi and Lantigua, {Laura A.} and Frederick Michaud and Sharon Goldberg and Lages, {Lucas C.} and Higuera, {Oscar L.} and Andrea Fiallo and Eduard Tiozzo and Judi Woolger and Stephanie Ciraula and Mendez, {Armando J} and Rodriguez, {Allan E} and Janet Konefal",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/19390211.2018.1494661",
language = "English (US)",
journal = "Journal of Dietary Supplements",
issn = "1939-0211",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind Placebo-Control Trial

AU - Lewis, John E

AU - Atlas, Steven E.

AU - Abbas, Muhammad H.

AU - Rasul, Ammar

AU - Farooqi, Ashar

AU - Lantigua, Laura A.

AU - Michaud, Frederick

AU - Goldberg, Sharon

AU - Lages, Lucas C.

AU - Higuera, Oscar L.

AU - Fiallo, Andrea

AU - Tiozzo, Eduard

AU - Woolger, Judi

AU - Ciraula, Stephanie

AU - Mendez, Armando J

AU - Rodriguez, Allan E

AU - Konefal, Janet

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The primary objective of the study was to evaluate the effects of a hydrolyzed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, hepatic, and renal function in HIV + individuals. A six-month randomized double-blind placebo-controlled trial was utilized to conduct the intervention. Forty-seven HIV + participants on stable antiretroviral therapy were enrolled and randomly assigned to one of the two study conditions (n = 22 RBAC and n = 25 placebo) and consumed 3 gram/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months follow-up for CD4+ and CD8+, liver enzymes, and kidney function. No side effects were reported, and liver and kidney markers nearly remained completely within normal limits. The percentage change in CD4+ was similar for the placebo (+2.2%) and RBAC (+3.1%) groups at 6 months follow-up. The percentage change in CD8+ count significantly decreased from baseline to 6 months in the RBAC group (−5.2%), whereas it increased in the placebo group (+57.8%; p = 0.04). The CD4+/CD8+ ratio improved clinically in the RBAC group from 0.95 (SD =0.62) at baseline to 1.07 (SD =0.11) at 6 months, whereas it declined in the placebo group from 0.96 (SD =0.80) at baseline to 0.72 (SD =0.59) at 6 months. Our results showed a statistically significant decrease in CD8+ count and a clinically significant increase in CD4+/CD8+ ratio for the RBAC group compared to the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.

AB - The primary objective of the study was to evaluate the effects of a hydrolyzed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, hepatic, and renal function in HIV + individuals. A six-month randomized double-blind placebo-controlled trial was utilized to conduct the intervention. Forty-seven HIV + participants on stable antiretroviral therapy were enrolled and randomly assigned to one of the two study conditions (n = 22 RBAC and n = 25 placebo) and consumed 3 gram/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months follow-up for CD4+ and CD8+, liver enzymes, and kidney function. No side effects were reported, and liver and kidney markers nearly remained completely within normal limits. The percentage change in CD4+ was similar for the placebo (+2.2%) and RBAC (+3.1%) groups at 6 months follow-up. The percentage change in CD8+ count significantly decreased from baseline to 6 months in the RBAC group (−5.2%), whereas it increased in the placebo group (+57.8%; p = 0.04). The CD4+/CD8+ ratio improved clinically in the RBAC group from 0.95 (SD =0.62) at baseline to 1.07 (SD =0.11) at 6 months, whereas it declined in the placebo group from 0.96 (SD =0.80) at baseline to 0.72 (SD =0.59) at 6 months. Our results showed a statistically significant decrease in CD8+ count and a clinically significant increase in CD4+/CD8+ ratio for the RBAC group compared to the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.

KW - arabinoxylan

KW - CD4-CD8 ratio

KW - CD8

KW - dietary supplements

KW - HIV infections

KW - immune system phenomena

KW - polysaccharides

UR - http://www.scopus.com/inward/record.url?scp=85055479030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055479030&partnerID=8YFLogxK

U2 - 10.1080/19390211.2018.1494661

DO - 10.1080/19390211.2018.1494661

M3 - Article

AN - SCOPUS:85055479030

JO - Journal of Dietary Supplements

JF - Journal of Dietary Supplements

SN - 1939-0211

ER -